2-Apr-2026
No headlines found.
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Thu, 12-Mar 8:00 AM ET)
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Filana Therapeutics trades on the NASDAQ stock market under the symbol FLNA.
As of April 2, 2026, FLNA stock price climbed to $1.73 with 290,631 million shares trading.
FLNA has a market cap of $83.57 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that FLNA belongs to (by Net Assets): IWC, DFAS, AVSC, QQQS, DFMC.
FLNA support price is $1.66 and resistance is $1.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FLNA shares will trade within this expected range on the day.